Boyaa Bio: Plans to transfer 100% equity of Nanjing Xinbai Pharmaceutical for approximately 235 million yuan

Boya Biological announces that the company and its wholly owned subsidiary Jiangxi Boya Pharmaceutical Investment Co., Ltd. have signed the “Equity Transfer Agreement of Nanjing Xinbai Pharmaceutical Co., Ltd.” to transfer 100% equity of Nanjing Xinbai Pharmaceutical Co., Ltd. to China Resources Shuanghe for 235 million yuan. This transaction constitutes a related-party transaction, and related directors will abstain from voting.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin